semaglutide in heart failure VisualAbstract: Improves Outcomes Patients with Obesity-Related and Type 2 Diabetes Weight loss drug's heart benefits

Most common adverse events at all doses: Nausea (3355%, dose-related) Vomiting (1335%) Decreased appetite (1528%) Constipation or diarrhea (1020%) Injection-site reaction (510%) Dose-related dysesthesia signal: The TRIUMPH-4 trial identified a dose-related dysesthesia (nerve-tingling, paresthesia) signal: This is the most-flagged trial-level safety signal for retatrutide and the reason community doses cluster at 2-4 mg/week well below where the dysesthesia signal becomes prominent

Timing your injection in the evening so the peak nausea window occurs during sleep

If you are not seeing results on semaglutide or experiencing unexpected hunger, a protein audit may reveal that your limited calories are going to carbs and fats instead of the protein your body is craving

Medicare will offer GLP-1 weight-loss drugs through a bridge program from July 1 through Dec

These challenges make the decision-making process around GLP-1s complex

In one legal complaint, Eli Lilly alleged Mochi Health had engaged in deceptive business tactics